![L. Scott McGinnis, MD](https://treatcancer.com/wp-content/uploads/2022/06/L.-Scott-McGinnis-MD-SERO-e1656467477472.png)
L. Scott McGinnis, MD
workRadiation Oncologist
location_onNovant Health Weisiger Cancer Institute
About Dr. McGinnis
Board Certification
June 7, 1995
Licensure
North Carolina #93-00229
South Carolina #16669
Professional Organizations
ASTRO
American College of Radiology Guidelines and Standards Committee of the Radiation Oncology Commission – 2006-2008
North Carolina Medical Society
Mecklenberg Medical Society
Southeast Consortium for Cancer Care
Awards & Affiliations
![Top Doctors - Charlotte 2023](https://treatcancer.com/wp-content/uploads/2022/06/Top-Radiation-Oncology-Doctors-2023-Charlotte-Magazine.png)
![Top Doctors - Charlotte 2020](https://treatcancer.com/wp-content/uploads/2022/02/2020-top-doctors-charlotte.jpg)
![](https://treatcancer.com/wp-content/uploads/2022/02/top-doctors-charlotte-magazine.jpg)
![](https://treatcancer.com/wp-content/uploads/2022/06/Medical-College-of-Georgia-e1655948420576.jpeg)
Education
University of Alabama at Birmingham
Birmingham, Alabama
Residency, Radiation Oncology
Medical College of Georgia
Augusta, Georgia
Degree: M.D.
Vanderbilt University
Nashville, Tennessee
Degree: B.A. English/French
Employment
SERO
Charlotte, NC
Selected Meeting Presentations
- Co-Investigator, The Beta-Cath System Trial. A Prospective, Randomized, Placebo-controlled, Triple-masked Trial to Evaluate the Safety and Effectiveness of the Novoste Beta-Cath System in Native Coronary Arteries. (Novoste/CDAC) (N=80)